Despite declining rates of use among adults, 15% of adults in the United States were cigarette smokers in 2015. Of those, more than 22 million said they’d like to quit.
Drug Store News sat down with Chester “Chip” Davis, president and CEO of the Association for Accessible Medicines, to discuss how the generics industry is adapting to a changing market, and new opportunities manufacturers may be looking to pursue.
As the generics industry squares off against price deflation, manufacturers are looking for new product areas in need of lower-cost alternatives — and recent Food and Drug Administration efforts are helping with the discovery process.
Heplisav-B is the first new hepatitis B vaccine in the United States in more than 25 years and the only two-dose hepatitis B vaccine for adults.
The recent discovery of the endocannabinoid system, from 1990 to 1993, within the body and the research of hemp/cannabis on it, as well as the legal clarity and risk mitigation, are racing us to a category market explosion.
Packaging is the distillation of the brand’s identity and purpose, so it’s essential to understand the regulatory constraints very early on in the brand design process.
Alex Azar was president of Eli Lilly from 2012 until January 2017, having joined the company in 2007 as senior vice president of corporate affairs and communications.
Prohibited under the S1 Anabolic Agent category of the World Anti-Doping Agency Prohibited List, SARMs have raised serious concerns for FDA, USADA and the legitimate dietary supplement industry.
The NIH is currently researching a "precision medicine" approach to managing diabetes, where a person’s genes, environment, lifestyle and other factors all help determine the best treatment plan.
The report, issued at the commission’s final meeting Wednesday, includes recommendations that were part of suggestions made to the Administration by industry organizations.